26 July 2013 - Deborah Wilkes
Archived
Regulatory agencies in Europe and the US have taken action against oral medicines containing ketoconazole, including Johnson & Johnson's Nizoral, because they are associated with a risk of liver injury. Topical formulations are not affected by the measures.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.